FTC backs insurer in Amgen patent monopoly case — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amgen is defending its acquisition of a patent application in a court case that could determine whether such moves constitute anticompetitive behavior to prolong market exclusivity for a drug.
- UnitedHealthcare is suing Amgen, arguing the patent application purchase was a tactic to delay generic competition and maintain high prices on a medicine.
- Federal Trade Commission has joined the case on the side of payers, asserting that acquiring early-stage patent rights may violate antitrust laws if used to suppress competition.
- U.S. patent system practices are under scrutiny as the litigation highlights how patent application acquisitions might be leveraged to extend monopolies beyond statutory limits.
Why it matters: If courts rule that buying patent applications to block generics is anticompetitive, drugmakers like Amgen could face tighter constraints on IP strategies, potentially accelerating generic entry and lowering costs for insurers and patients — a shift with broad implications for pharmaceutical pricing power.
Ask SkimNews
